Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Trial ID or NCT#
Status
Purpose
The purpose of this study is to determine the diagnostic utility of 89Zr-panitumumab to identify metastatic lesion(s) in subjects with head and neck squamous cell carcinoma (HNSCC).
Official Title
Phase II Study Evaluating Zr-Panitumumab for Assessment of Suspected Metastatic Lesions on 18F-FDG-PET/CT in Head and Neck Squamous Cell Carcinoma
Eligibility Criteria
- * Age ≥ 19 years.* Biopsy confirmed diagnosis of squamous cell carcinoma of the head and neck.* Subjects diagnosed with any T stage, any subsite within the head and neck. Subjects with recurrent disease or a new primary will be allowed.* Must have standard of care 18F-FDG-PET/CT scan ≤ 30 days of Day 0 with suspected metastatic lesions.* Have acceptable hematological status, coagulation status, kidney function, and liver function including the following clinical results:
- * Hemoglobin ≥ 9gm/dL * White blood cell count \> 3000/mm3 * Platelet count ≥ 100,000/mm3 * Serum creatinine ≤ 1.5 times upper reference range * PTT = 11.5 - 14.4 seconds * INR = 0.9 - 1.2
- * Myocardial infarction (MI); cerebrovascular accident (CVA); uncontrolled congestive heart failure (CHF); significant liver disease; or unstable angina within 6 months prior to enrollment* History of infusion reactions to other monoclonal antibody therapies* Pregnant or breastfeeding* Magnesium or potassium lower than the normal institutional values* Subjects receiving Class IA (quinidine, procainamide) or Class III (dofetilide, amiodarone, sotalol) antiarrhythmic agents* Subjects with a history or evidence of interstitial pneumonitis or pulmonary fibrosis* Severe renal disease or anuria* Known hypersensitivity to deferoxamine or any of its components
Investigator(s)
Contact us to find out if this trial is right for you.
Contact
Roan C Raymundo, BS
650-721-4071
View on ClinicalTrials.gov